Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Chemistry and Biology

Volumn 22, Issue 6, 2015, Pages 755-763

  Lu, Jing ^a   Qian, Yimin ^a   Altieri, Martha ^a   Dong, Hanqing ^a   Wang, Jing ^a   Raina, Kanak ^a   Hines, John ^b   Winkler, James D ^a   Crew, Andrew P ^a   Coleman, Kevin ^a   Crews, Craig M ^b,c  

^a Arvinas Inc   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; ARV 825; BRD4 PROTEIN; BROMODOMAIN INHIBITOR; CASPASE 3; CASPASE 7; CEREBLON PROTEIN; MYC PROTEIN; PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; ACETANILIDE DERIVATIVE; ARV-825; AZEPINE DERIVATIVE; BIRABRESIB; BRD4 PROTEIN, HUMAN; CRBN PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; NUCLEAR PROTEIN; PEPTIDE HYDROLASE; THALIDOMIDE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAUDI CELL LINE; DOWN REGULATION; DRUG DESIGN; DRUG INHIBITION; GENE REPRESSION; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACETANILIDES; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; NUCLEAR PROTEINS; PEPTIDE HYDROLASES; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; THALIDOMIDE; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84931560527     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.05.009     Document Type: Article

References (40)

1. I.A. Asangani, V.L. Dommeti, X. Wang, R. Malik, M. Cieslik, R. Yang, J. Escara-Wilke, K. Wilder-Romans, S. Dhanireddy, and C. Engelke Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Nature 510 2014 278 282
2. M.G. Baratta, A.C. Schinzel, Y. Zwang, P. Bandopadhayay, C. Bowman-Colin, J. Kutt, J. Curtis, H. Piao, L.C. Wong, and A.L. Kung An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma Proc. Natl. Acad. Sci. USA 112 2015 232 237
3. A.C. Belkina, and G.V. Denis BET domain co-regulators in obesity, inflammation and cancer Nat. Rev. Cancer 12 2012 465 477
4. M. Boi, E. Gaudio, P. Bonetti, I. Kwee, E. Bernasconi, C. Tarantelli, A. Rinaldi, M. Testoni, L. Cascione, and M. Ponzoni The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs Clin. Cancer Res. 21 2015 1628 1638
5. J.E. Bolden, N. Tasdemir, L.E. Dow, J.H. van Es, J.E. Wilkinson, Z. Zhao, H. Clevers, and S.W. Lowe Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition Cell Rep. 8 2014 1919 1929
6. D.L. Buckley, and C.M. Crews Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system Angew. Chem. Int. Ed. Engl. 53 2014 2312 2330
7. J.C. Burnett, J.J. Rossi, and K. Tiemann Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol. J. 6 2011 1130 1146
8. M. Ceribelli, P.N. Kelly, A.L. Shaffer, G.W. Wright, W. Xiao, Y. Yang, L.A. Mathews Griner, R. Guha, P. Shinn, and J.M. Keller Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Proc. Natl. Acad. Sci. USA 111 2014 11365 11370
9. B. Chapuy, M.R. McKeown, C.Y. Lin, S. Monti, M.G. Roemer, J. Qi, P.B. Rahl, H.H. Sun, K.T. Yeda, and J.G. Doench Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma Cancer Cell 24 2013 777 790
10. J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, E. Kastritis, T. Gilpatrick, R.M. Paranal, and J. Qi BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 2011 904 917
11. P. Fernandez, P. Scaffidi, E. Markert, J.H. Lee, S. Rane, and T. Misteli Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4 Cell Rep. 9 2014 248 260
12. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, and I. Felletar Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
13. E.S. Fischer, K. Bohm, J.R. Lydeard, H. Yang, M.B. Stadler, S. Cavadini, J. Nagel, F. Serluca, V. Acker, and G.M. Lingaraju Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Nature 512 2014 49 53
14. C.A. French, C.L. Ramirez, J. Kolmakova, T.T. Hickman, M.J. Cameron, M.E. Thyne, J.L. Kutok, J.A. Toretsky, A.K. Tadavarthy, and U.R. Kees BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells Oncogene 27 2008 2237 2242
15. M. Gabay, Y. Li, and D.W. Felsher MYC activation is a hallmark of cancer initiation and maintenance Cold Spring Harbor Perspect. Med. 4 2014
16. C. Ge, G. Muller, R. Chen, and M. Saindane Process for the preparation of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione compounds US Pat. Appl. 2007 US 2007/0004920
17. S. Hoelder, P.A. Clarke, and P. Workman Discovery of small molecule cancer drugs: successes, challenges and opportunities Mol. Oncol. 6 2012 155 176
18. S.J. Howell, S.R. Johnston, and A. Howell The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer Best Pract. Res. Clin. Endocrinol. Metab. 18 2004 47 66
19. T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, and H. Handa Identification of a primary target of thalidomide teratogenicity Science 327 2010 1345 1350
20. D.S. Johnson, E. Weerapana, and B.F. Cravatt Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2 2010 949 964
21. K. Klapproth, and T. Wirth Advances in the understanding of MYC-induced lymphomagenesis Br. J. Haematol. 149 2010 484 497
22. M. Loosveld, R. Castellano, S. Gon, A. Goubard, T. Crouzet, L. Pouyet, T. Prebet, N. Vey, B. Nadel, and Y. Collette Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL Oncotarget 5 2014 3168 3172
23. A. Lopez-Girona, D. Mendy, T. Ito, K. Miller, A.K. Gandhi, J. Kang, S. Karasawa, G. Carmel, P. Jackson, and M. Abbasian Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Leukemia 26 2012 2326 2335
24. J. Loven, H.A. Hoke, C.Y. Lin, A. Lau, D.A. Orlando, C.R. Vakoc, J.E. Bradner, T.I. Lee, and R.A. Young Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 153 2013 320 334
25. G. Lu, R.E. Middleton, H. Sun, M. Naniong, C.J. Ott, C.S. Mitsiades, K.K. Wong, J.E. Bradner, and W.G. Kaelin Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins Science 343 2014 305 309
26. J.A. Mertz, A.R. Conery, B.M. Bryant, P. Sandy, S. Balasubramanian, D.A. Mele, L. Bergeron, and R.J. Sims 3rd Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. USA 108 2011 16669 16674
27. J. Noel, K. Iwata, S. Ooike, K. Sugahara, H. Nakamura, and M. Daibata Development of the BET bromodomain inhibitor OTX015 Mol. Cancer Ther. 12 2014 C244
28. A. Puissant, S.M. Frumm, G. Alexe, C.F. Bassil, J. Qi, Y.H. Chanthery, E.A. Nekritz, R. Zeid, W.C. Gustafson, and P. Greninger Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discov. 3 2013 308 323
29. K. Raina, and C.M. Crews Chemical inducers of targeted protein degradation J. Biol. Chem. 285 2010 11057 11060
30. K.M. Sakamoto, K.B. Kim, A. Kumagai, F. Mercurio, C.M. Crews, and R.J. Deshaies Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. USA 98 2001 8554 8559
31. K.M. Sakamoto, K.B. Kim, R. Verma, A. Ransick, B. Stein, C.M. Crews, and R.J. Deshaies Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell Proteomics 2 2003 1350 1358
32. J.S. Schneekloth Jr., and C.M. Crews Chemical approaches to controlling intracellular protein degradation Chembiochem 6 2005 40 46
33. J.S. Schneekloth Jr., F.N. Fonseca, M. Koldobskiy, A. Mandal, R. Deshaies, K. Sakamoto, and C.M. Crews Chemical genetic control of protein levels: selective in vivo targeted degradation J. Am. Chem. Soc. 126 2004 3748 3754
34. Q. Shao, A. Kannan, Z. Lin, B.C. Stack Jr., J.Y. Suen, and L. Gao BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo Cancer Res. 74 2014 7090 7102
35. J. Shi, and C.R. Vakoc The mechanisms behind the therapeutic activity of BET bromodomain inhibition Mol. Cell 54 2014 728 736
36. T. Shimamura, Z. Chen, M. Soucheray, J. Carretero, E. Kikuchi, J.H. Tchaicha, Y. Gao, K.A. Cheng, T.J. Cohoon, and J. Qi Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer Clin. Cancer Res. 19 2013 6183 6192
37. H. Sueoka, H. Kobayashi, S. Ehara, and H. Komatsu Preparation and formulation of thienotriazolodiazepine derivatives for the treatment of inflammatory intestinal diseases, venous insufficiency, and venous ulcer PCT Int. Appl. 1998 WO 9811111 A1 19980319
38. A. Wyce, Y. Degenhardt, Y. Bai, B. Le, S. Korenchuk, M.C. Crouthame, C.F. McHugh, R. Vessella, C.L. Creasy, and P.J. Tummino Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer Oncotarget 4 2013 2419 2429
39. J. Zuber, J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, and M. Wunderlich RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478 2011 524 528
40. J. Zuber, J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, and M. Wunderlich RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478 2011 524 528